Connect with us

NEWS

Hope rises for COVID-19 prevention Morderna vaccine

Published

on

A UNITED States based biotech firm, Moderna, today announced that its phase-one human trial for a coronavirus vaccine produced COVID-19 antibodies in every one of its participants.

  According to Chief Medical Officer at Moderna, Tal Zaks, two vaccine doses of 25 micrograms showed that, by day 43 of the trials, humans developed antibody levels consistent with those who have recovered from coronavirus, the company said.

  “Participants who received 100-microgram doses had antibodies that “significantly exceeded levels” found in recovered patients. These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 micrograms,” Zaks said.

Explaining further, Zaks said that the trial also found that the vaccine produced neutralising antibodies in at least eight participants — four of whom received a 25-microgram dose. This, he stated, is coming while the other four received 100 mcg.

  “When tested against a live virus, Moderna said the levels of neutralising antibodies were at or above levels seen in blood samples. When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralising antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” Zaks added.

  But this news has set prices of Moderna’s stock on bearish rally ahead of Monday’s opening bell.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending